Therefore, this study proposes the scientific hypothesis that Cirsiliol improves DCM cardiac injury by synergistically activating the PPAR-α/AMPK pathway to inhibit high-glucose-induced mitochondrial membrane potential loss, Bax/Bcl-2-mediated apoptosis, and IL-6/MCP-1-driven inflammation. Here, BCL2 is linked to familial dilated cardiomyopathy.